Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RB1 | P06400 | 6/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.52 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTR5A | P47898 | 1/20 | 0.49 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 1/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2309545 | 0.88 | NR2E1 (0.60) | SIRT1NR2E1KDM4EDRD5MAPKAPK2 | |
| SCHEMBL12660565 | 0.88 | NR2E1 (0.60) | SIRT1NR2E1KDM4EDRD5MAPKAPK2 | |
| SCHEMBL31078875 | 0.88 | NR2E1 (0.60) | SIRT1NR2E1KDM4EDRD5MAPKAPK2 | |
| SCHEMBL8592516 | 0.87 | SIRT1 (0.68) | RB1SIRT1NR2E1KDM4EHTR5A | |
| SCHEMBL31078487 | 0.86 | CYP2D6 (0.52) | NR2E1KDM4EDRD5 | |
| SCHEMBL4287532 | 0.86 | CYP2D6 (0.52) | NR2E1KDM4EDRD5 | |
| Hydrochloric Acid SCHEMBL8595142 | 0.86 | SIRT1 (0.67) | RB1SIRT1NR2E1KDM4EHTR5A | |
| SCHEMBL11680918 | 0.82 | SIRT1 (0.58) | SIRT1DRD2DRD1DRD5MAPKAPK2 | |
| SCHEMBL13011891 | 0.81 | SIRT1 (0.52) | RB1SIRT1NR2E1KDM4EHTR5A | |
| SCHEMBL11680201 | 0.81 | KMT2A (0.62) | SIRT1KDM4EDRD2MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| EP-1848426-B1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER FLEMING LTD (GB) | 2012-08-01 | — | — | EP | disclosed |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-6175015-B1 | USEFUL IN THE TREATMENT OF SCHIZOPHRENIA, DEPRESSION, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE AND OTHER DISORDERS THAT RESPOND TO DOPAMINERGIC BLOCKADE, AND FOR TREATING SIDE EFFECTS OF NEUROLEPTIC AGENTS | NEUROGEN CORPORATION | 2001-01-16 | — | — | US | disclosed |
| EP-0923574-A1 | FUSED INDOLECARBOXAMIDES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5892041-A | NERVOUS SYTEM AND PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1998055115-A1 | CARBOXAMIDES USEFUL AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-12-10 | — | — | WO | disclosed |
| WO-1998006717-A9 | FUSED INDOLECARBOXAMIDES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | — | 1998-07-23 | — | — | WO | disclosed |
| WO-1998006717-A1 | FUSED INDOLECARBOXAMIDES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
| US-4057559-A | ANTIINFLAMMATORY AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-11-08 | — | — | US | disclosed |
| US-4009181-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIRHEUMATIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-02-22 | — | — | US | disclosed |
| US-3868387-A | 1,2,3,4-TETRAHYDROCARBAZOLE-2-CARBOXYLIC ACIDS AND THEIR DERIVATIVES | HOFFMANN LA ROCHE | 1975-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HCRTR1, CDR2, MSR1 | RB1 1021/4885SIRT1 301/4885NR2E1 90/4885 |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | PTGES2, PTGES, PTGS2 | RB1 3631/4885SIRT1 1491/4885NR2E1 911/4885 |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | PTGES2, PTGES, PTGS2 | RB1 3631/4885SIRT1 1491/4885NR2E1 911/4885 |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HCRTR1, CDR2, MSR1 | RB1 1021/4885SIRT1 301/4885NR2E1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.